Novasep-PharmaZell invests €7.3M to increase API production capacity at Mourenx site
-
With support from the French government "France Relance" Plan, this €7.3M investment allows the Group to expand ongoing efforts to modernize equipment and increase production capacity at its site in Mourenx
-
The initial priority will be to create a new pilot workshop for API production
-
This workshop will be operational in Q2 2023 and be focused on handling innovative and highly active products including cancer treatments
Lyon (France) & Raubling (Germany), July 21st 2022 ‐ The Novasep‐PharmaZell Group has announced a €7.3M investment for its Mourenx site (southwestern France), as part of a larger project supported by the "France Relance" Plan, to create a multipurpose pilot workshop within one of its production units. This new industrial tool will support the growth of the Mourenx site and sustain the growing demand for production of active pharmaceutical ingredients(APIs), particularly the highly potent drugs (HPAPIs) used to treat cancer.
This investment includes an upgrade of two existing 2000‐liter reactors to optimize their versatility and functionality, together with the addition of a new 1500‐liter reactor & Hastelloy filter‐dryer. The new multi‐purpose workshop will be equipped to produce batches ranging from 30 to 100 kg for clinical trials, process validation and commercial production of APIs for targeted therapies, with a focus on HPAPIs.
"This major project to modernize and expand the Mourenx site demonstrates our new Group's determination to pursue the strategy of industrial investments that we have been successfully deploying for several years”, says Jean Bléhaut, President of the CDMO Business Unit. "This is a clear and practical answer for our pharmaceutical customers, who face growing challenges to secure supply chains in the field of healthcare products, and particularly APIs.”
"Creating this unit is an opportunity to diversify the Mourenx site's activity with a new state‐of‐the‐art production tool that improves our capacity for handling highly potent therapeutic products", adds Patrick Suescun, Mourenx Site Director. "This will clearly be beneficial to our clients and their patients, as well as to our local teams, who will be working with the best equipment to fulfill our commitments."
Since the completion of the Novasep‐PharmaZell merger, announced on April 7th, the new Group's strategy is focused on offering its customers greater competitiveness, secure supply chains, and full support throughout the life cycle of their products.
About Novasep
Novasep offers flexible contract development & manufacturing (CDMO) solutions for small molecule APIs & biopharmaceuticals to innovators. We propose a wide range of flexible cGMP manufacturing assets on multiple sites with an outstanding regulatory track record. We are a world leader in a number of specialized technologies including HPAPIs, ADCs, hazardous & cryogenic chemistry & industrial chromatography (batch and continuous).
About PharmaZell
PharmaZell is a market leader in the highly resilient and specialty API market where it has a diversified portfolio of over 70 APIs and enjoys leading industry positions in several products that treat respiratory, inflammatory, and liver diseases. Many of the company’s products require special handling procedures and/or technologies. Headquartered in Raubling (near Munich), PharmaZell operates four state-of-the-art production and R&D sites in Germany, Italy, and India with over 900 employees globally.
Press Contact
Thomas Goldberg
+33 (0)6 03 78 55 63
2022 07_Investment Mourenx_Pilote_DE final
2022 07_Investment Mourenx_Pilote_EN final
Back to our full list of News